breast-cancer

New nanoplatform blocks tumor cells from expelling damaged mitochondria—cutting breast cancer metastasis.

Mitocytosis expels damaged mitochondria via migrasomes, conferring resistance to mitochondria-targeted therapy. Researchers developed RH-NPs dual nanoplatform: TL/RH-NPs damage tumor mitochondria; CGT/RH-NPs block mitocytosis by inhibiting integrin signaling when cells attempt mitochondrial…

New nanoplatform blocks tumor cells from expelling damaged mitochondria—cutting breast cancer metastasis.

Key Findings

Mitocytosis confers resistance to mitochondria-targeted therapy in high-migrasome tumors
RH-NPs dual platform: TL/RH-NPs damage mitochondria; CGT/RH-NPs block mitocytosis
CGT/RH-NPs hitchhike with damaged mitochondria into migrasomes to block expulsion
Combination significantly enhanced anti-metastatic efficacy in 4T1 breast tumor models
Establishes mitocytosis inhibition as a new therapeutic target

Implications

Targeting mitocytosis represents a novel approach to overcoming resistance in breast cancer. Strategy applicable to other cancers with high migrasome expression.

Caveats

Preclinical mouse model; abstract-only. Safety profiles of individual nanoparticle components need characterization. Manufacturing complexity adds translational challenges.

Source: Science advances — 2026-04-10

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

New nanoplatform blocks tumor cells from expelling damaged mitochondria—cutting breast cancer metastasis.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database